PharmEnable are delighted to announce the appointment of Dr Jane Dancer as Chair of our Board of Directors. She brings with her a wealth of experience in business development and driving company growth. Her previous roles include Chief Business Officer at F-star Biotechnology Ltd, a clinical-stage biopharmaceutical company. Prior to this, Dr Dancer was Vice President of Business Development at Cellzome Ltd and Director of Business Development at Cambridge Antibody Technology, later acquired by AstraZeneca. On joining PharmEnable as Chair, Dr Dancer said, “I am delighted to be joining the Board of a fast-growing company like PharmEnable. I look forward to supporting the team in building the company and bringing a new generation of drugs to the market for previously untreatable conditions.” Dr Dancer is the Chair of the Sir Richard Stapley Educational Trust and was named in BioBeat’s top 50 leading female scientists and innovators in healthcare in 2017. She holds an MA and PhD in Natural Sciences from the University of Cambridge and has an MBA from the Cambridge Judge Business School. Dr Hannah Sore, Founder and CEO of PharmEnable, said: “We are delighted to welcome Jane to PharmEnable as Chair. Her background and extensive experience will be invaluable to the company as we focus on the next phase of business growth.”
